Creator: Help Dementia Editorial Team
Published: 2026-04-12T01:25:14

Reviewed by the Help Dementia Editorial Team — our editors review every article for accuracy against guidance from the National Institute on Aging, the Alzheimer’s Association, and peer-reviewed sources.

Protease biology sits at the center of this dementia and brain health question.

Recent breakthroughs in protease biology have identified several promising new drug targets for Alzheimer’s disease, moving beyond the amyloid-beta hypothesis that has dominated research for decades. Scientists have discovered that specific enzymes—proteins that break down other proteins—play critical roles in the disease process, and manipulating these proteases offers a fresh approach to slowing or preventing cognitive decline. For example, researchers have engineered neural stem cells to produce an Aβ-degrading protease called NEP directly on cell membranes, a technique that could eventually be delivered to Alzheimer’s patients to clear toxic protein buildup in the brain.

The significance of this research lies in its scope and specificity. Rather than pursuing broad protein-reducing strategies that caused serious side effects in previous trials, scientists are now targeting individual proteases with precision. Among the most important discoveries is that BACE1, a key enzyme in amyloid production, can be inhibited to reduce amyloid-beta levels by approximately 30%—a therapeutic threshold that shows promise without the toxicity problems that plagued earlier drug candidates. This represents a fundamental shift in how researchers understand Alzheimer’s biology and a move toward treatments grounded in how the brain actually breaks down and processes harmful proteins.

What Are Proteases and Why Do They Matter in Alzheimer’s Disease?
BACE1 Inhibition—A More Refined Approach to Amyloid Reduction
Engineering New Proteases—The NEP Approach and Beyond
The Rise of Non-Amyloid, Non-Tau Drug Targets
Understanding Protease Biology in Alzheimer’s Brain Tissue
The NU-9 Breakthrough in Clearing Toxic Oligomers
The Future of Protease-Targeted Alzheimer’s Therapies
Conclusion

What Are Proteases and Why Do They Matter in Alzheimer’s Disease?

Proteases are enzymes that cleave proteins into smaller fragments, and they are essential to virtually every biological process in the brain. In the context of Alzheimer’s disease, two proteases became central to research: BACE1 and γ-secretase, both of which are required to produce amyloid-beta from a larger precursor protein. When these enzymes work together, they generate the Aβ molecules that accumulate into plaques in Alzheimer’s brains. This seemingly straightforward understanding led researchers to hypothesize that blocking these proteases would prevent disease. However, the reality proved far more complex.

The protease γ-secretase, in particular, illustrates why targeting enzymes requires caution. While inhibiting γ-secretase would stop amyloid production, this protease actually performs essential functions by cleaving over 200 different protein substrates at cell membranes. When researchers attempted to block it in clinical trials, patients experienced severe on-target toxicity—unwanted side effects directly caused by the drug working exactly as intended. This discovery forced the field to abandon γ-secretase inhibition as a viable approach, despite its theoretical elegance. The lesson shifted focus toward more selective targets like BACE1, which shows potential for meaningful amyloid reduction while maintaining a safer profile.

What Are Proteases and Why Do They Matter in Alzheimer's Disease?

BACE1 Inhibition—A More Refined Approach to Amyloid Reduction

BACE1 has emerged as the preferred protease target in the amyloid pathway, but success requires hitting a specific threshold: drug candidates must demonstrate the ability to reduce amyloid-beta by approximately 30% while maintaining acceptable safety profiles. This precise requirement reflects hard-won knowledge from earlier drug development efforts, where compounds either failed to reduce Aβ sufficiently or produced unexpected neurological side effects. The 30% reduction target represents a balance—enough to show clinical benefit in theory, but conservative enough to minimize risks to essential cellular processes. One important limitation of BACE1 inhibition is that it addresses only one part of the problem.

Even if a drug successfully reduces new amyloid production by 30%, patients still have decades of Aβ that has already accumulated in their brains. This is why many researchers emphasize that BACE1 inhibitors are most likely to help people in early stages of cognitive decline or those with elevated amyloid who have not yet developed symptoms. For patients with moderate to advanced dementia, reducing future amyloid production may not reverse existing damage. Furthermore, because BACE1 also has functions beyond amyloid generation, blocking it could potentially affect other important neurological processes that scientists are still investigating.

Engineering New Proteases—The NEP Approach and Beyond

Rather than simply blocking problematic enzymes, some researchers are taking an opposite approach: engineering cells to produce more of proteases that degrade amyloid-beta. The most promising example involves NEP (neutral endopeptidase), a natural protease that breaks down amyloid-beta and has been shown to clear Aβ from the brain in animal models. Scientists have now engineered neural stem cells to express NEP on their cell membranes and in exosomes—small cellular packages that can travel between cells. These engineered cells are combined with PBAE-PLGA nanoparticles, specially designed carriers that improve how neural stem cells differentiate and survive in the brain.

This engineered approach represents a fundamentally different strategy than traditional small-molecule drugs. Instead of taking a pill daily, patients might eventually receive a single injection of engineered cells that continuously produce Aβ-degrading enzymes in the brain. Early work shows this method can clear toxic amyloid oligomers—small clusters of Aβ that are particularly damaging to neurons—more effectively than BACE1 inhibition alone. The advantage is clear: creating a persistent biological factory to clean up amyloid. However, the complexity and cost of cell engineering therapies remain significant barriers, and long-term safety data in humans is still being collected.

Engineering New Proteases—The NEP Approach and Beyond

The Rise of Non-Amyloid, Non-Tau Drug Targets

A major shift in Alzheimer’s drug development has taken place over the past few years. According to the latest analysis, 70% of Alzheimer’s disease drugs currently in clinical trials are targeting mechanisms beyond amyloid and tau—the two proteins that have dominated the field for two decades. This reflects a growing recognition that other proteases and proteins also contribute significantly to neurodegeneration. Comprehensive proteomic studies of Alzheimer’s brains have identified 866 consensus protein alterations, revealing novel disease-associated proteins including MDK/PTN, NTN1, SMOC1, GPNMB, NPTX2, NRN1, VGF, and U1 snRNP components.

These non-traditional targets offer advantages and tradeoffs compared to amyloid and tau approaches. The advantage is that many of these proteins are involved in inflammation, mitochondrial dysfunction, or synaptic loss—mechanisms that may be more directly responsible for the cognitive symptoms patients experience. By targeting these pathways, drugs might produce more noticeable improvements in memory and thinking. The tradeoff is that these newer targets are less well-characterized, so clinical trials are often longer and less certain of success. Additionally, a patient’s Alzheimer’s disease may be driven by different combinations of these protein alterations, suggesting that future treatment may require personalized drug combinations rather than one-size-fits-all therapies.

Understanding Protease Biology in Alzheimer’s Brain Tissue

Direct study of Alzheimer’s brain tissue has revealed that the protease dysregulation extends far beyond simple overproduction of amyloid-beta. Multi-cohort analyses comparing healthy brains to those affected by Alzheimer’s disease have identified widespread alterations in how different proteases are expressed and regulated. Some proteases are overactive, some are underactive, and some are present in locations where they normally would not appear. This complex landscape suggests that Alzheimer’s disease involves a disruption of the entire protease ecosystem in the brain, not just two key enzymes. One important warning from this research is that modifying any single protease can have ripple effects throughout the brain.

Because proteases work in interconnected networks and perform multiple functions, inhibiting one may inadvertently affect the activity of others. This is why newer drug candidates are being tested with great caution in patient populations. Early detection of side effects and careful monitoring of cognitive outcomes remain essential. Additionally, protease dysregulation may contribute to the “amyloid-independent” aspects of dementia—the neurodegeneration that occurs even without amyloid accumulation. Understanding this full protease picture is crucial before deploying protease-targeting drugs to large populations.

Understanding Protease Biology in Alzheimer's Brain Tissue

The NU-9 Breakthrough in Clearing Toxic Oligomers

Among recent protease-related breakthroughs, NU-9 has demonstrated particular promise in clearing toxic amyloid-beta oligomers in lab-grown brain cells from the hippocampus—the brain region critical for memory formation. Unlike BACE1 inhibitors that reduce the production of new Aβ, NU-9 works by directly degrading existing amyloid oligomers, the small toxic clusters that are thought to be more damaging than larger amyloid plaques. In hippocampal cell cultures, NU-9 showed the ability to clear these oligomers more effectively than many previous candidates.

The significance of this finding is that it demonstrates another viable protease-based strategy: enhancing the brain’s natural ability to remove amyloid that has already formed. This approach complements BACE1 inhibition (which prevents new amyloid) and could potentially be combined with other therapies for greater effect. Early-stage data suggests NU-9 has a favorable safety profile in cellular models, though it remains years away from human clinical trials. The challenge ahead is determining whether clearing oligomers in isolated brain cells translates to cognitive benefits in living patients with Alzheimer’s disease.

The Future of Protease-Targeted Alzheimer’s Therapies

The convergence of protease biology research, advanced proteomics, and improved drug delivery technologies suggests that Alzheimer’s treatments in the coming decade will be more sophisticated and more targeted than current options. Rather than broad approaches to reducing amyloid or tau, future therapies will likely involve multiple agents working through different protease pathways simultaneously. Combination therapies—perhaps pairing BACE1 inhibition with oligomer-clearing compounds and non-amyloid protease modulators—may become the standard of care for newly diagnosed patients. This evolution also points toward personalized medicine in dementia care.

As researchers continue to map the specific protease dysregulations in individual patients, treatments could be tailored based on each person’s unique molecular profile. A patient with prominent inflammation-related protease changes might receive a different regimen than one driven primarily by tau pathology. The tools to implement this precision medicine are emerging, though the infrastructure to deliver it at scale remains underdeveloped. What is clear is that protease biology has opened entirely new avenues for Alzheimer’s research, and the next generation of drugs will be shaped by these discoveries.

Conclusion

Protease biology research has identified multiple new drug targets that offer hope for slowing or preventing Alzheimer’s disease, moving beyond the limitations of earlier approaches focused solely on amyloid-beta. Key advances include refined BACE1 inhibition targeting a 30% reduction in amyloid, innovative cell-engineering approaches using NEP-producing neural stem cells, and emerging drugs like NU-9 that clear toxic amyloid oligomers. Simultaneously, the discovery of 866 consensus protein alterations in Alzheimer’s brains has revealed that 70% of the current drug pipeline is pursuing non-amyloid, non-tau mechanisms—recognition that effective treatment likely requires addressing multiple disease pathways.

For individuals concerned about Alzheimer’s disease or caring for someone with dementia, this research landscape offers realistic optimism tempered by caution. While these new protease targets represent genuine scientific progress, most are still in early or mid-stage clinical trials, meaning several more years of testing lie ahead before new treatments reach patients. In the interim, the established interventions—cognitive engagement, cardiovascular health, quality sleep, and social connection—remain the most reliable ways to support brain health. As protease-targeted therapies advance through testing, working with healthcare providers to stay informed about clinical trial opportunities may be an option worth exploring for those in early disease stages.